

Gaiane M Rauch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8176543/publications.pdf>

Version: 2024-02-01

49
papers

1,285
citations

430874

18
h-index

377865

34
g-index

49
all docs

49
docs citations

49
times ranked

1770
citing authors

#	ARTICLE	IF	CITATIONS
1	Bracketing with Multiple Radioactive Seeds to Achieve Negative Margins in Breast Conservation Surgery. <i>Clinical Breast Cancer</i> , 2022, 22, e158-e166.	2.4	6
2	MRI-guided Breast Biopsy Case-based Review: Essential Techniques and Approaches to Challenging Cases. <i>Radiographics</i> , 2022, 42, E46-E47.	3.3	2
3	Mid-treatment Ultrasound Descriptors as Qualitative Imaging Biomarkers of Pathologic Complete Response in Patients with Triple-Negative Breast Cancer. <i>Ultrasound in Medicine and Biology</i> , 2022, , .	1.5	2
4	Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 1323.	3.7	4
5	A model combining pretreatment MRI radiomic features and tumor-infiltrating lymphocytes to predict response to neoadjuvant systemic therapy in triple-negative breast cancer. <i>European Journal of Radiology</i> , 2022, 149, 110220.	2.6	13
6	Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 2878-2889.	7.0	10
7	Quantitative Apparent Diffusion Coefficients From Peritumoral Regions as Early Predictors of Response to Neoadjuvant Systemic Therapy in <sc>Tripleâ€Negative</sc> Breast Cancer. <i>Journal of Magnetic Resonance Imaging</i> , 2022, 56, 1901-1909.	3.4	6
8	A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer. <i>Investigational New Drugs</i> , 2021, 39, 509-515.	2.6	18
9	Identification of breast cancer patients with pathologic complete response in the breast after neoadjuvant systemic treatment by an intelligent vacuum-assisted biopsy. <i>European Journal of Cancer</i> , 2021, 143, 134-146.	2.8	44
10	Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC). <i>Breast Cancer Research and Treatment</i> , 2021, 185, 1-12.	2.5	10
11	MRI Staging in an Evolving Management Paradigm for Rectal Cancer, From the <i>AJR</i> Special Series on Cancer Staging. <i>American Journal of Roentgenology</i> , 2021, 217, 1282-1293.	2.2	7
12	Monte Carlo simulation of pixelated CZT detector with Geant4: validation of clinical molecular breast imaging system. <i>Physics in Medicine and Biology</i> , 2021, 66, 125009.	3.0	4
13	Imaging of Noncalcified Ductal Carcinoma <i>In Situ</i>. <i>Journal of Clinical Imaging Science</i> , 2021, 11, 34.	1.1	7
14	Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5365-5375.	7.0	29
15	Assessment of Early Response to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer Using Amide Proton Transferâ€weighted Chemical Exchange Saturation Transfer MRI: A Pilot Study. <i>Radiology Imaging Cancer</i> , 2021, 3, e200155.	1.6	12
16	Developing an intraoperative 3T MRI-guided brachytherapy program within a diagnostic imaging suite: Methods, process workflow, and value-based analysis. <i>Brachytherapy</i> , 2020, 19, 427-437.	0.5	12
17	Axillary ultrasound during neoadjuvant systemic therapy in triple-negative breast cancer patients. <i>European Journal of Radiology</i> , 2020, 130, 109170.	2.6	4
18	Molecular Breast Imaging-guided Percutaneous Biopsy of Breast Lesions: A New Frontier on Breast Intervention. <i>Journal of Breast Imaging</i> , 2020, 2, 484-491.	1.3	9

#	ARTICLE	IF	CITATIONS
19	Rectal cancer lexicon: consensus statement from the society of abdominal radiology rectal & anal cancer disease-focused panel. <i>Abdominal Radiology</i> , 2019, 44, 3508-3517.	2.1	22
20	Patient Selection for Clinical Trials Eliminating Surgery for HER2-Positive Breast Cancer Treated with Neoadjuvant Systemic Therapy. <i>Annals of Surgical Oncology</i> , 2019, 26, 3071-3079.	1.5	19
21	MRI for Radiation Therapy Planning in Human Papillomavirus-associated Gynecologic Cancers. <i>Radiographics</i> , 2019, 39, 1476-1500.	3.3	4
22	Molecular Breast Imaging in Evaluating Breast Cancer Extent of Disease. <i>Journal of Breast Imaging</i> , 2019, 1, 155-156.	1.3	0
23	MR staging of anal cancer: what the radiologist needs to know. <i>Abdominal Radiology</i> , 2019, 44, 3726-3739.	2.1	13
24	Imaging features of triple-negative breast cancers according to androgen receptor status. <i>European Journal of Radiology</i> , 2019, 114, 167-174.	2.6	14
25	Digital Breast Tomosynthesis for Intraoperative Margin Assessment during Breast-Conserving Surgery. <i>Annals of Surgical Oncology</i> , 2019, 26, 1720-1728.	1.5	22
26	Locally recurrent rectal cancer: what the radiologist should know. <i>Abdominal Radiology</i> , 2019, 44, 3709-3725.	2.1	15
27	Ductal Carcinoma In Situ and Margins &mm. <i>Annals of Surgery</i> , 2019, 269, 150-157.	4.2	29
28	Biopsy Feasibility Trial for Breast Cancer Pathologic Complete Response Detection after Neoadjuvant Chemotherapy: Imaging Assessment and Correlation Endpoints. <i>Annals of Surgical Oncology</i> , 2018, 25, 1953-1960.	1.5	36
29	Comparison of Breast MR Imaging with Molecular Breast Imaging in Breast Cancer Screening, Diagnosis, Staging, and Treatment Response Evaluation. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2018, 26, 273-280.	1.1	14
30	A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy. <i>Annals of Surgery</i> , 2018, 267, 946-951.	4.2	147
31	ASO Author Reflections: Elimination of Breast Cancer Surgery in Complete Responders After Neoadjuvant Chemotherapy: Imaging Perspective. <i>Annals of Surgical Oncology</i> , 2018, 25, 628-629.	1.5	1
32	A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR- β . <i>Investigational New Drugs</i> , 2018, 36, 1103-1109.	2.6	13
33	High risk breast lesions identified on MRI-guided vacuum-assisted needle biopsy: outcome of surgical excision and imaging follow-up. <i>British Journal of Radiology</i> , 2018, 91, 20180300.	2.2	25
34	Imaging-Concordant Benign MRI-Guided Vacuum-Assisted Breast Biopsy May Not Warrant MRI Follow-Up. <i>American Journal of Roentgenology</i> , 2017, 208, 916-922.	2.2	11
35	Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery. <i>JAMA Surgery</i> , 2017, 152, 665.	4.3	149
36	Diffusion-Weighted Magnetic Resonance Imaging as a Predictor of Outcome in Cervical Cancer After Chemoradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 546-553.	0.8	48

#	ARTICLE	IF	CITATIONS
37	Multimodality Imaging for Evaluating Response to Neoadjuvant Chemotherapy in Breast Cancer. American Journal of Roentgenology, 2017, 208, 290-299.	2.2	83
38	DCIS Margins and Breast Conservation: MD Anderson Cancer Center Multidisciplinary Practice Guidelines and Outcomes. Journal of Cancer, 2017, 8, 2653-2662.	2.5	38
39	Development and validation of a rapid and robust method to determine visceral adipose tissue volume using computed tomography images. PLoS ONE, 2017, 12, e0183515.	2.5	18
40	Comparison of Computed Tomography-based and Magnetic Resonance Imaging-based Clinical Target Volume Contours at Brachytherapy for Cervical Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 96, 793-800.	0.8	18
41	Molecular Breast Imaging: Role as a Screening Modality. Current Breast Cancer Reports, 2016, 8, 230-235.	1.0	2
42	Microcalcifications in 1657 Patients with Pure Ductal Carcinoma in Situ of the Breast: Correlation with Clinical, Histopathologic, Biologic Features, and Local Recurrence. Annals of Surgical Oncology, 2016, 23, 482-489.	1.5	41
43	Correlation Between Sonographic Findings and Clinicopathologic and Biologic Features of Pure Ductal Carcinoma In Situ in 691 Patients. American Journal of Roentgenology, 2015, 204, 878-888.	2.2	27
44	Optimizing packing contrast for MRI-based intracavitary brachytherapy planning for cervical cancer. Brachytherapy, 2015, 14, 385-389.	0.5	3
45	Optimization of MR Imaging for Pretreatment Evaluation of Patients with Endometrial and Cervical Cancer. Radiographics, 2014, 34, 1082-1098.	3.3	61
46	Dosimetric Predictors of Duodenal Toxicity After Intensity Modulated Radiation Therapy for Treatment of the Para-aortic Nodes in Gynecologic Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 88, 357-362.	0.8	62
47	Clinicopathologic, mammographic, and sonographic features in 1,187 patients with pure ductal carcinoma in situ of the breast by estrogen receptor status. Breast Cancer Research and Treatment, 2013, 139, 639-647.	2.5	32
48	Outcome Analysis of 9-Gauge MRI-Guided Vacuum-Assisted Core Needle Breast Biopsies. American Journal of Roentgenology, 2012, 198, 292-299.	2.2	115
49	To Look or Not to Look? Yes to Nodal US!. Journal of Breast Imaging, 0, , .	1.3	4